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The genetics of complex disease is entering a new and exciting era.The exponentially growing knowledge and
technological capabilities emerging from the human genome project have finally reached the point where rele-
vant genes can be readily and affordably identified. As a result, the last12 months has seen a virtual explosion in
new knowledge with reports of unequivocal association to relevant genes appearing almost weekly.The impact
of these new discoveries in Neuroscience is incalculable at this stage but potentially revolutionary. In this review,
an attempt is made toilluminate some of the mysteries surrounding complex genetics. Although focused almost
exclusively on multiple sclerosis all the points made are essentially generic and apply equally well, with relatively
minor addendums, to any other complex trait, neurological or otherwise.
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Evidence for the influence of genetics
Most, if not all, common diseases are characterized by an
increased frequency in the relatives of affected individuals,
and multiple sclerosis is no exception. Amongst white
individuals living in temperate regions, the prevalence of
multiple sclerosis is typically 1/1000, yet 15–20% of patients
report a family history of the disease, a rate which is sig-
nificantly more than would be expected by chance
(Compston and Coles, 2002). Several carefully conducted,
population-based studies of familial recurrence risk have
been performed which have confirmed and quantified the
increased risk of the disease in the relatives of affected
individuals (Sadovnick et al., 1988; Robertson et al., 1996;
Carton et al., 1997). This familial clustering can be usefully
summarized in terms of s; the relative risk of the disease
seen in the siblings of affected individuals as compared
to that seen in the general population (Risch, 1990).
In multiple sclerosis this risk ratio takes a value of ~15
(Sawcer, 2006), and of course reflects the combined effects
of all shared aetiological influences, both genetic and
environmental (Guo, 2002). Teasing apart the relative
contribution of these alternate influences requires the
analysis of informative groups and many such studies
have been performed in multiple sclerosis. A significant
excess of concordance in monozygotic (identical) as
compared to dizygotic (non-identical) twins is a virtually
universal finding (Mumford et al., 1994; Willer et al., 2003;
Hansen et al., 2005; Ristori et al., 2006; Islam et al., 2006),
with the only exceptions being studies which lacked the
power to show any difference as significant (French
Research Group on Multiple Sclerosis, 1992). In a study
of individuals with multiple sclerosis who had been adopted
in early life, researchers found no excess risk of the disease
in the adopting family but the expected excess risk within
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Couples where both the husband and the wife are affected
with the disease (so-called conjugal pairs) do not occur
more frequently than would be expected by chance,
although the risk of the disease in their offspring is greater
than if just one parent is affected (Robertson et al., 1997;
Ebers et al., 2000). The risk of the disease in half-siblings is
approximately half the risk seen in full siblings, regardless
of whether they are raised together or apart (Ebers et al.,
2004), while there is no excess risk in stepsiblings (Dyment
et al., 2006), who are of course genetically unrelated.
In summary, these data suggest that living with someone
who has, or who will eventually develop, multiple sclerosis
has little or no effect on your risk of developing the disease
unless you are genetically related to them, in which case
your risk increases with the degree of relatedness (Dyment
et al., 2006). This is not to imply that environmental factors
have no role, only that they seem to exert their effects
mainly at a population level with the micro-environmental
differences between families within a given population
seeming to be of relatively little importance (Dyment et al.,
2006). Although these data confirm that genetic factors are
unequivocally relevant in multiple sclerosis, large extended
families containing multiple affected individuals in multiple
generations are extremely uncommon (Willer et al., 2007).
Most families contain no more than two or three affected
individuals and no clear mode of inheritance can be
inferred from segregation analysis (Compston et al., 2006).
The epidemiology of multiple sclerosis continues to be
scrutinized and interesting nuances will no doubt continue
to emerge. However, it is important to recognize the
limitations of this approach. These studies are extremely
difficult to perform and frequently subject to confounding
and bias. Moreover, although multiple sclerosis is a
‘common’ disease in neurological practice, the relatively
modest frequency of the disease in the population as a
whole (1/1000) means that even huge population-based
studies can only provide crude estimates for recurrence
risks, and other basic epidemiological parameters, such as
age-specific incident rates and life time risk, all of which
come with large confidence intervals. It seems likely that
most, if not all, of any apparent inconsistencies in the
epidemiology of multiple sclerosis stem from the variability
inherent in underpowered studies. In light of these
considerations, it is easy to see why predictable effects,
such as the Carter effect, have only inconsistent support
(Hupperts et al., 2001; Ebers et al., 2004; Kantarci et al.,
2006; Herrera et al., 2007) (see Supplementary material
section 1). In a complex disease like multiple sclerosis
where epidemiological parameters are impossible to mea-
sure reliably and multiple potentially conflicting effects are
likely to exist, it seems unlikely that epidemiological
analysis will ever provide any major insights. In short,
epidemiological analysis has convincingly shown us that
genetic factors are relevant but lacks any power to
illuminate the nature or extent of these factors beyond
indicating that multiple genes are involved (Wang et al.,
2005; Lindsey, 2005).
Early success
Initial attempts to identify genes influencing susceptibility
to multiple sclerosis were highly successful and quickly
identified the now well-established relevance of the Major
Histocompatibility Complex (MHC). Unfortunately, this
early success has been followed by several decades of
frustration in which no other undeniably relevant loci
emerged until 2007. Before contemplating why it has been
so difficult to map non-MHC loci, it is worth revisiting the
MHC association, its discovery and subsequent dissection.
Association between the Human Leukocyte Antigens
(HLA) and multiple sclerosis was first identified in 1972.
Using cell culture-based methods researchers from
California found association with HLA-A3 (Naito et al.,
1972) while others from Denmark found association with
HLA-B7 (Jersild et al., 1972). The following year the same
Danish group also established association with DR2 (Jersild
et al., 1973). The nomenclature used to describe HLA is
complex and has evolved considerably over the years. At the
time of these original discoveries very different designations
were used, such that the phenotypes associated with the
HLA-A3, HLA-B7 and DR2 alleles were known respectively
as HL-A3, HL-A7 and LD-7a. It was quickly realised that
these were not independent associations but were rather a
reflection of linkage disequilibrium (LD, see Supplementary
material section 2) between the corresponding alleles and
association of the disease with a haplotype including these
alleles (Compston et al., 1976; Terasaki et al., 1976). The
molecular genetic dissection of these associations began in
1984 when Cohen et al. (1984) used analysis of restriction
fragment length polymorphisms to directly establish
association with the HLA-DR2 allele (Cohen et al., 1984).
Over the years, technology has improved and the resolution
of the associated alleles has been refined (Vartdal et al.,
1989; Olerup and Hillert, 1991).
All of these associated HLA genes lie in the MHC, a
gene-dense region of the genome characterized by extensive
LD and extreme levels of polymorphism (Horton et al.,
2004). In light of these features, it is not unsurprising to
find that many variants from other genes in this region also
show association with multiple sclerosis (Lincoln et al.,
2005; Yeo et al., 2007). The modest levels of LD between
the class I region (containing the HLA-A and HLA-B genes)
and the class II region (containing the DRB1 and DQB1
genes) enabled researchers to quickly establish that associa-
tion primarily derived from the class II region (Compston
et al., 1976; Terasaki et al., 1976). However, the more
extensive LD between DRB1 and DQB1 made it much
more difficult to refine which of these genes was primarily
responsible for the association. Studying African American
patients, who have less intense LD between DRB1
 1501 and
DQB1
 0602, Oksenberg et al. (2004) provided the first
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the DRB1 gene, an observation which has been confirmed
in subsequent studies in large cohorts of patients of
European descent (Yeo et al., 2007). Because of further
evolution in the nomenclature of HLA genes what was
previously called DR2, is these days referred to as DR15; the
DRB1
 1501 allele is the most common sub type of DR15
seen in white Europeans.
Looking back at some of these original studies in light of
current knowledge is highly informative. Even though the
extent of linkage disequilibrium between HLA-A3 and HLA-
DRB1
 1501 is modest (D0 =0.3, r
2=0.14) the original study
by Naito et al. (1972), which included 94 cases and 871
controls, had450% power to identify association with A3at
the 5% level. This early study thus illustrates well the principle
that genuine associations can indeed be identified by typing
markers in LD with real effects even when the level of LD is
modest. Of course the saving grace for Naito et al. (1972) was
the strength of the association with the DRB1
 1501 allele and
their use of a large cohort of controls. In the study by
Compstonetal.(1976),aclassIIlocuswasconsidereddirectly
and nominally significant association was confirmed using
just 83 cases and 32 controls.
It is now well established that the association of multiple
sclerosis with the DRB1
 1501 allele is almost ubiquitous,
the relevance of this allele having been confirmed in
virtually every population tested (Compston et al., 2006).
The fact that other MHC haplotypes also influence
susceptibility is well established (Marrosu et al., 1998)
and recent data indicate that the risk associated with
 1501
may be modified depending upon which other MHC
haplotype is carried in the heterozygous state (Dyment
et al., 2005; Barcellos et al., 2006; Ramagopalan et al.,
2007). However, it is unclear whether these additional
signals stem primarily from the DRB1 gene or from the
effects of other MHC loci. Many researchers have found
evidence supporting the existence of an independent
signal from the class I region (Fogdell-Hahn et al., 2000;
Marrosu et al., 2001; de Jong et al., 2002; Rubio et al., 2002;
Harbo et al., 2004; Yeo et al., 2007) although not all
(Lincoln et al., 2005). Again, this apparent inconsistency is
not unexpected. Establishing the presence of additional
susceptibility loci located close to a primary locus is
complex especially in the presence of prominent LD and
likely allelic heterogeneity (Koeleman et al., 2000). Once
correction for the effects of LD with the DRB1
 1501 allele
are made, the residual power in even the largest of these
studies is modest (Dyment et al., 2005; Lincoln et al., 2005;
Barcellos et al., 2006; Yeo et al., 2007). A role for the
DRB1 03 haplotype seems beyond doubt (Dyment et al.,
2005; Barcellos et al., 2006; Yeo et al., 2007) and Sardinian
data would suggest that this association most likely stems
from the DRB1 gene (Marrosu et al., 2001). Beyond this it
is clear that the MHC contains further signals but their
nature and origins are as yet unresolved.
By cataloguing variation in the MHC through the
re-sequencing of specific haplotypes (Allcock et al., 2002;
Horton et al., 2008), and empirically establishing the
complex patterns of LD across the region (Miretti et al.,
2005), it has been possible to establish a comprehensive
panel of haplotype tagging single nucleotide polymorphisms
(SNPs) (de Bakker et al., 2006). These SNPs are currently
being typed in multiple sclerosis and a number of other
autoimmune diseases as part of the International MHC and
Autoimmunity Genetics Network project. Hopefully, these
systematic fine-mapping efforts will help to unravel this
complex association, although it can be anticipated that
large sample sizes will be needed to confirm the findings
emerging from this project.
The rest of the genome
Outside the MHC, the genetic analysis of multiple sclerosis
has been considerably less successful, with no consistent
findings emerging until very recently. This lack of any
convincing progress has been a source of great frustration,
andtheinconsistencyinearlyclaimshasrightlybeencriticized
(Hirschhorn et al., 2002). It is now clear that two main issues
have confounded the identification of relevant genes—the
modest size of effects attributable to individual loci (Ioannidis
et al., 2006) and a failure to correctly allow for the statistical
consequences that result from the enormous size of the
genome (Ioannidis, 2003). The search for the genes of
relevance in multiple sclerosis has reasonably been likened
to searching for a handful of rather small needles in a very
large haystack (Hensiek et al., 2003b).
The needles
Obviously we cannot know a priori what effects on risk will
be conferred by individual susceptibility alleles, nor can we
know their frequency or mode of inheritance. However,
linkage analysis has provided us with invaluable guidance
regarding an upper limit on these effects sizes, which
researchers cannot afford to ignore.
The fact that association with the MHC can reliably be
detected with modest resources (c 100 cases and 100
controls) and yet only accounts for a fraction of the
heritability seen in multiple sclerosis meant that in the late
1980s and early 1990s there was an expectation that non-
MHC loci would be rather easy to find. At this time, there
was a feeling that perhaps susceptibility to multiple sclerosis
might be determined by just a handful of effects similar, or
perhaps even larger, to that conferred by the MHC.
Coincident with this the human genome project reached
the point where systematic whole-genome screening for
linkage became possible (see section 3 of Supplementary
material). In 1996, the results of whole-genome screens for
linkage to multiple sclerosis from the UK, the US and
Canada were published back to back (Ebers et al., 1996;
Haines et al., 1996; Sawcer et al., 1996). Each of these
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300–400 microsatellite markers. Subsequently similar stud-
ies were performed in multiplex families from Finland
(Kuokkanen et al., 1997), Sardinia (Coraddu et al., 2001),
Italy (Broadley et al., 2001), Scandinavia (Akesson et al.,
2002), Australia (Ban et al., 2002) and Turkey (Eraksoy
et al., 2003), and in addition each of the original three
groups extended their analysis using further families and
more microsatellite markers (Hensiek et al., 2003a; Dyment
et al., 2004; Kenealy et al., 2004). Interestingly, none of
these studies identified any statistically significant linkage,
not even in the region of the MHC. Attempts at meta-
analysis were no more successful, although linkage to the
MHC just reached genome-wide significance in some of
these studies (Ligers et al., 2001; GAMES and the
Transatlantic Multiple Sclerosis Genetics Cooperative,
2003). Contemplating the reasons for this disappointing
lack of linkage, the International Multiple Sclerosis Genetics
Consortium (IMSGC) identified a number of issues which
might have confounded these studies (IMSGC, 2004) and in
an attempt to correct for these re-screened the genome for
linkage using a dense map of SNPs in families from
Australia, Scandinavia, the US and the UK (IMSGC, 2005).
In the final analysis, this substantially larger study included
data from 4506 SNPs typed in 730 multiplex families which
between them provided almost 1000 affected relative pairs.
The increased power provided by this screen in comparison
with its predecessors is evident from the overwhelming
evidence for linkage found in the MHC region where a lod
score of 11.7 was observed (IMSGC, 2005). Once again,
however, no other region of statistically significant linkage
was apparent. The comprehensive marker map used in this
study makes it virtually impossible that any signals of a
magnitude similar to that attributable to the MHC could
have been missed. As with the previous studies the number
of suggestive linkage peaks was significantly greater than
would have been expected by chance alone (IMSGC, 2005),
indicating that there is excess allele sharing but providing
no clear guide as to the location of relevant genes.
Although these linkage data provide no useful informa-
tion concerning the location of non-MHC susceptibility loci
the observed allele sharing does provide useful guidance
concerning the size of effects attributable to such loci
(Risch, 1990). Employing the approach suggested by Risch
and Merikangas (1996), and remembering that the observed
allele sharing is expected to provide a significantly inflated
estimate of effect size (Goring et al., 2001), it is
straightforward to show that common non-MHC risk
alleles are highly unlikely to increase risk by more than a
factor of 2.0. Under these circumstances, it is clear that
further linkage analysis is almost certain to be unrewarding
since the number of sib pair families necessary to
demonstrate significant linkage is impractically large
(Risch and Merikangas, 1996) (see Supplementary material
section 3). Fortunately, association-based studies are sig-
nificantly more powerful and thus provide a means to
identify genes exerting effects which fall below the
resolution of linkage (Risch and Merikangas, 1996).
However, even the most optimistic estimates of effect size
consistent with the available linkage data indicate that
association studies will need to involve at the very least 500
cases and 500 controls (Sawcer, 2006). Since most of the
published literature regarding the genetics of multiple
sclerosis has been based on significantly smaller numbers
one corollary of this is that almost all previous studies have
been seriously underpowered. There are virtually no loci,
with the possible exception of APOE (Burwick et al., 2006),
where published studies have been adequately powered to
confidently exclude the possibility of a meaningful effect. It
seems highly likely that many of the entirely plausible
candidates considered to have been excluded on the basis of
the absence of any consistent evidence to date will even-
tually emerge as genuinely relevant in the disease. Coupling
this limited effect size with the fact that for most genes no
more than a tiny fraction of the variation has ever been
tested, it is clear that few if any genes have received a
thorough analysis. It is surely the virtual absence of any
power that is responsible for nearly all the apparent incon-
sistency in the literature concerning the genetics of complex
diseases such as multiple sclerosis (Lohmueller et al., 2003).
Of course, it remains possible that a large extended
family in which a rare more penetrant allele is segregat-
ing might be found, and that the identification of such an
allele might be informative regarding the pathogenesis of
the disease, much as the identification of mutations in the
alpha-synuclein gene has been informative regarding the
pathogenesis of Parkinson’s disease (Polymeropoulos et al.,
1997). However, analysis of the few such families so far
reported has failed to identify any significant linkage let
alone any relevant loci (Dyment et al., 2002; Modin et al.,
2003). These larger families are characterized by multiple
affected siblings rather than multiple affected generations,
rarely show the greater degree of consistency in phenotype
that would be expected but instead show an increased
frequency of DRB1
 1501 carriage, the reverse of what
would be expected if a non-MHC locus were primarily
responsible for the disease (Willer et al., 2007). It also
remains possible that some otherwise rare alleles of higher
penetrance might have drifted through a genetic bottleneck
and thereby become frequent in a population isolate.
However, given the surprising extent of identity by descent
seen in apparently unrelated individuals (Frazer et al.,
2007), it is hard to imagine that there will be much power
to separate such alleles through homozygosity mapping.
The haystack
Although there are no clear data regarding the genetic
architecture underlying susceptibility to multiple sclerosis
considerable progress has been made concerning the nature
and extent of genetic variation in the human population in
general (Frazer et al., 2007). The human genome is roughly
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and is on average 99.9% identical between any two
individuals (International HapMap Project, 2003).
Although the total number of variants in the human
population runs into billions, the majority of these are
vanishingly rare (Kruglyak and Nickerson, 2001) and as a
result most (~90%) of the differences between any two
individuals is attributable to common variants, where both
the alleles are seen in at least 1% of the population (Wang
et al., 2005). In light of these observations, two competing
theories regarding the nature of susceptibility to complex
disease have emerged. The first, the so-called common
disease/common variant hypothesis (Reich and Lander,
2001; Pritchard and Cox, 2002), holds that susceptibility to
common disease is determined by a few common variants
with low penetrance, while the second, the heterogeneity
(or multiple rare variant) hypothesis (Smith and Lusis,
2002), holds that the notion of a common disease is
essentially a misnomer and that in fact such ‘diseases’ are in
reality a collection of genetically distinct conditions each
determined by a rare variant of higher penetrance.
Although these two hypotheses represent opposite extremes,
they are not mutually exclusive and it has been argued that
perhaps the most parsimonious expectation is that both will
be involved to some extent (Wang et al., 2005), with some
genuine heterogeneity but the bulk of the disease being
determined by common variants of low penetrance. It is
possible to estimate the number of variants that might
account for a disease like multiple sclerosis (Lindsey, 2005;
Yang et al., 2005); under the common disease/common
variant hypothesis just 20–100 common alleles each with a
modest Genotypic Relative Risk (GRR) (in the order of
1.2–1.5) would be sufficient, while under the multiple rare
variant model many hundreds if not thousands of rare
alleles would be required even if the GRR attributable to
each was considerable (in the order of 10–20) (Yang et al.,
2005). [See Risch and Merikangas (1996) and the
Supplementary material for the definition of GRR].
Following this logic we might expect that perhaps 100
common variants exerting modest effects on risk (i.e. of low
penetrance) are involved in determining susceptibility to
multiple sclerosis, and might also expect that a small
portion of the disease will turn out to have a distinct
genetic basis related to rarer rather more penetrant alleles.
Given that there are estimated to be some 10 million
common variants in the human population as a whole
(Kruglyak and Nickerson, 2001) we can see that the odds
that any randomly selected common variant is relevant in
multiple sclerosis is ~100000:1 against (assuming that there
is no significant LD between the various risk alleles).
By calculating the power of a study to identify any
particular level of significance (Purcell et al., 2003) and
using the above estimate for the prior odds we can
determine the odds that a result with any particular level of
significance is a true positive (see Supplementary material
section 4). Figure 1 shows the posterior odds for studies of
differing size assuming that the risk alleles relevant in
multiple sclerosis are common (frequency 10%) and have a
GRR of 1.3 (under a multiplicative model).
From this figure, we can see that P-values in the range of
5–0.1% will virtually always be false positives, even in well-
powered studies. This primarily occurs because the prior
odds are so extreme that it remains more likely that this
level of significance has arisen by chance in an unassociated
marker than that we happen to have considered a genuinely
associated marker. As the P-value becomes more extreme
the probability of seeing such a result by chance alone is
reduced (by definition) and therefore it becomes increas-
ingly likely that the result is a true positive. While this is
intuitively expected it is perhaps counter-intuitive to see
that the smaller the study (i.e. the less power in a study) the
greater the level of significance needs to be before a result
becomes more likely to be true than false (WTCCC, 2007).
For studies involving 1000 cases and 1000 controls we can
see that only P-values510
–8 are more likely to be true than
false. In less well powered studies, such as those using just
200 cases and 200 controls, even such extreme P-values
remain 100–1000 times more likely to be false than true.
The Wellcome Trust Case Control Consortium (WTCCC)
proposed this Bayesian approach and through similar
reasoning have recommended that association studies in
complex disease should involve at least 2000 cases and 2000
controls, in which case P-value of55 10
–7 will more often
be true than false (WTCCC, 2007). Comparing the different
curves in Fig. 1 it is clear that a considerable amount is
gained by increasing the sample size from 200 to 2000,
while, for effects of this size, relatively little is gained by
Fig. 1 Posterior Odds that a result is true, assuming risk alleles
with a frequency of10% and a Genotype Relative Risk (GRR) of1.3
and a multiplicative model.This figure indicates the posterior odds
that a result is true (plotted on a log scale on the y-axis) against
the significance of the result (plotted as -log of the P-value on the
x-axis).Five sample sizes are listed in the legend, in each the
number of cases and controls are equal, the 200line thus indicates
the posterior odds for a study involving 200 cases and 200 controls
and so on. Power was calculated using the on-line genetic power
calculator (Purcell et al., 2003).
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for effects of smaller magnitude the value of large sample
sizes becomes clear (Fig. 2).
These figures illustrate the need for adequate power. It is
only when studies have sufficient power that we can rely on
the prediction that P-values of55 10
–7 will more often be
true than false. Figure 3 shows the sample size required in
order to ensure that P-values of 55 10
–7 will indeed be
more often true than false in terms of the GRR conferred
by susceptibility loci.
In the analysis presented above, it has been assumed that
the variant chosen for study has been selected at random
from amongst the full list of common variation. In practice,
researchers do not do this but instead tend to use some
prior knowledge or existing information to guide the
selection of ‘candidates’. Of course, the validity of these
prior data cannot be known and assumptions used to guide
the selection of candidates may be invalid. In this way, we
can imagine that random selection represents the worst-case
scenario. Information used to guide the selection of
candidates may come from many different sources such
as data from animal models, expression studies, biological
or pathological analysis. For example, the evidence that
multiple sclerosis is an autoimmune disease is overwhelm-
ing and makes any gene with immunological function a
logical candidate. However, since perhaps a fifth of genes
have an immunological function using this information to
guide the selection of candidates would only improve
the prior odds by a factor of 5 taking them from 100000:1
to 20000:1. These odds are certainly reduced but come
at a price since the likelihood of discovering non-
immunological genes of relevance has been greatly reduced.
Since non-synonymous coding variants and variants in
regulatory regions or splice sites are more likely to have a
functional effect than variants in silent non-coding regions
it has also been suggested that concentrating analysis on
these more functional relevant variants could also improve
the prior odds (Tabor et al., 2002). Using multiple available
sources of information to guide the selection of candidates
in a process known as genomic convergence has been
suggested (Hauser et al., 2003) but even this comprehensive
approach seems unlikely to improve the prior odds much
beyond 1000:1 (Wacholder et al., 2004). Figure 4 shows the
posterior odds for the study of an optimally selected
candidate variant, a situation which might be considered
the best-case scenario.
From this figure we can see that even for well-selected
candidates studied in cohorts involving as many as 1000
Fig. 3 Required sample size as a function of the GRR conferred
by susceptibility allele.The sample size required is plotted on a log
scale.The sample size indicates the number of cases required to
ensure that results with a P-value of55 10
^7 are twice as likely to
be true as false, assuming an equal number of controls, a
multiplicative model and risk allele frequency of10%. Sample sizes
were calculated using the on-line genetic power calculator
(Purcell et al., 2003).
Fig. 4 Posterior odds that a result is true, assuming candidate risk
alleles with a frequency of10%, a GRR of1.2, a multiplicative model
andprior odds of1000:1.The axes and samples sizes are as in Fig.1.
Power was calculated using the on-line genetic power calculator
(Purcell et al., 2003).
Fig. 2 Posterior Odds that a result is true, assuming risk alleles
with a frequency of10%, a GRR of1.2 and a multiplicative model.
The axes and samples sizes are as in Fig.1. Power was calculated
using the on-line genetic power calculator (Purcell et al., 2003).
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0.1%) are still much more likely to be false positives than
true. On the other hand, in a candidate gene study this
number of samples is sufficient to ensure the reliability of
more stringent P-values such as 5 10
–7.
It is expected that the frequency of risk alleles will vary
from locus to locus so it is reasonable to enquire how this
variable might influence the interpretation of results.
Figure 5 shows the relationship between Risk Allele
Frequency (RAF) and the power to identify meaningful
association (P-value 55 10
–7).
Inspection of Fig. 5 shows that the power drops
precipitously as the minor allele frequency (MAF) falls
below 20% (corresponding to RAF values of520 or480%)
even in large study cohorts. Once the MAF falls below 5%
there is virtually no power. On the other hand, for
intermediate values of RAF there is relatively little variation
in power.
The effects of heterogeneity on the ability to identify
common susceptibility variants is also worthy of considera-
tion. A degree of heterogeneity is to be expected (Wang
et al., 2005) and the extent to which this and other sources
of confounding, such as diagnostic inaccuracy, reduce the
power to identify association is clearly relevant. Figure 6
indicates the consequences of including phenocopies in the
case cohort (Gordon et al., 2002; Edwards et al., 2005).
From Fig. 6 it is clear that a surprisingly high level of
phenocopy inclusion can be tolerated. This observation
should not be interpreted as arguing for careless phenotyp-
ing, clearly power will be reduced every time a phenocopy
is mistakenly included in a study and every effort should be
made to keep this to a minimum. On the other hand, given
that a degree of heterogeneity is expected it is important to
realize that even if this amounted to as much as 10–15% of
the disease it would still be possible to identify relevant
common variants. Some evidence for heterogeneity in
multiple sclerosis has been identified although this probably
amounts to no more than 1–2% of the disease. In the early
1990s, it was realized that some patients with Leber’s
Hereditary Optic Neuropathy (an optic atrophy caused by
specific mutations in mitochondrial DNA) developed a
disease that, apart from the prominence of visual failure,
was clinically and radiologically indistinguishable from
multiple sclerosis (Harding et al., 1992; Riordan-Eva
et al., 1995). This condition is, however, extremely rare.
More recently investigators from the Mayo clinic (USA)
have established that in some cases inflammatory demye-
lination of the central nervous system results from auto-
antibodies directed against the water channel aquaporin-4
(Lennon et al., 2004, 2005), these antibodies thereby
providing the first biomarker distinguishing a pathogeni-
cally distinct subgroup of patients with CNS inflammatory
demyelinating disease (Lennon et al., 2004). Although the
main phenotypes associated with these antibodies, neuro-
myelitis optica (Devic’s disease), recurrent myelitis and
recurrent optic neuritis are highly distinctive at the clinical
level (Wingerchuk et al., 2006) it is clear that the phenotype
associated with these antibodies is expanding and we can
expect that a proportion of cases satisfying clinical
diagnostic criteria for multiple sclerosis (McDonald et al.,
2001) will in fact turn out to have this distinct antibody-
mediated disease. Outside these two rare conditions,
Fig. 6 Influence of phenocopyrate on power to identify significant
association (P-value55 10
^7).The phenocopy rate indicates the
proportion of cases which have been misdiagnosed as having the
disease when in fact they are controls. A phenocopy rate of 25%
thus indicates that1in 4 of the cases is a misdiagnosis (or hetero-
geneity). Since the prevalence of multiple sclerosis is 1per 1000 the
impact of using unselected controls is minimal; for example in a
cohort of 2000 unselected controls only two would be expected
to be cases and thus the impact on power and posterior odds is
imperceptible. Power was calculated under the assumption that
the susceptibility alleles have a GRR of1.3 and a multiplicative
model. Sample sizes are indicated in the legend, note these are not
all the same as in earlier figures. Power was calculated using the
on-line power for association with error (PAWE) calculator
(Gordon et al., 2002; Edwards et al., 2005).
Fig. 5 Influence of risk allele frequency (RAF) on power to iden-
tify significant association (P-value55 10
^7). Power was calcu-
lated under the assumption that the susceptibility alleles have a
GRR of1.3 and a multiplicative model. Sample sizes are indicated in
the legend. Power was calculated using the on-line genetic power
calculator (Purcell et al., 2003).
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multiple sclerosis.
Some investigators feel that primary progressive disease is
a distinct condition and should be considered separately
from relapse remitting disease, while others feel that this
apparent distinction is just a reflection of the fact that the
activity of the relapsing component of the disease is highly
variable, being essentially absent in some cases and
prominent in others. Detailed analysis of the natural history
of the disease has shown that progression is essentially
independent of relapse activity and indistinguishable
between primary progressive and relapse onset cases
(Compston, 2006; Confavreux and Vukusic, 2006a, b;
Kremenchutzky et al., 2006). In the same way, pathological
and radiological differences between primary progressive
and relapsing onset disease are largely a reflection of relapse
activity rather than being distinct. It seems likely that
genetic factors will influence the course of multiple
sclerosis, and there is evidence for a degree of concordance
within multiplex families with respect to course (Hensiek
et al., 2007). However, it also seems likely that in terms of
susceptibility factors there will be rather more in common
between primary progressive and relapsing disease than
different, certainly there is no convincing evidence for any
difference between these two groups in terms of the
susceptibility factors thus far established.
Genome-wide association studies (GWAS)
One logical way to improve the odds of identifying
susceptibility factors would be to consider all common
variation rather than just a single randomly selected or
candidate variant. If all common variation were to be typed
in a study then this study would be sure to include an
analysis of the relevant variants. In this situation, concerns
about prior odds might be ignored and tests simply
interpreted after some correction for multiple testing.
However, rather predictably, nothing is gained by adopting
this approach to analysis since the statistical penalty
required to correct for multiple testing is equivalent to
that incurred by allowing for the prior odds (Freimer and
Sabatti, 2004). This is not surprising since both are simply a
reflection of the size of the genome. This type of
comprehensive (direct) GWAS would seem to be ideal
but in fact the extent of LD between common variants is so
extensive that an indirect screen involving just a fraction of
the markers and relying on LD between tested and untested
variants, enables a large proportion (typically 480%) of
common variation to be screened in a highly efficient
manner (Pe’er et al., 2006). Direct GWAS remain beyond
affordable and practical technologies at this time but
indirect GWAS are possible and have proven to be a
highly successful means to identify common variants
influencing susceptibility to complex disease (Duerr et al.,
2006; Easton et al., 2007; Gudmundsson et al., 2007;
Hampe et al., 2007; Helgadottir et al., 2007; Hunter et al.,
2007; Libioulle et al., 2007; McPherson et al., 2007; Rioux
et al., 2007; Saxena et al., 2007; Scott et al., 2007; Sladek
et al., 2007; Stacey et al., 2007; Steinthorsdottir et al., 2007;
WTCCC, 2007; Yeager et al., 2007).
Testing for association indirectly introduces another
variable which influences the power to identify relevant
loci, the extent of LD between the tested variant and the
causative allele (Moskvina and O’Donovan, 2007). Figure 7
shows the effects of LD on power to identify meaningful
association in studies of differing size.
From Fig. 7 it is clear that power falls dramatically as LD
declines unless study samples are large enough as to ensure
‘reserve power’. In a study involving 10 000 cases and 10
000 controls there would be little difference in power
between causative variants and those in LD with r
240.8
(when considering variants with a frequency of 10% that
increase risk by a factor of 1.3 or more). In the context of
the MHC, even lower levels of LD can generate highly
significant associations at test markers as the signal from
the causative (DRB1
 1501) allele is so strong.
One of the most notable features of the GWAS
completed to date is the consistent observation that
association tests are modestly inflated at neutral markers
(i.e. those that do not influence susceptibility) in compar-
ison with what would be expected if sampling error were
the only source of variance. Exploring this systematic
Fig. 7 Influence of linkage disequilibrium (LD) between the tested
and causative variant on the power to identify significant associa-
tion (P-value55 10
^7).There is a simple relationship between the
extentof linkage disequilibrium and effective sample size (Wall and
Pritchard, 2003), such that the product ofr
2 (see Supplementary
material section 2) and actual sample size indicates the sample
size which would have yielded the same power if the causative
variant had been directly typed.This simple relationship was
used to calculate the effective sample size at each level ofr
2 and
thereby calculate the power recorded in the figure. In these calcu-
lations, the susceptibility allele was assumed to have a frequency
of10%, a GRR of1.3 and a multiplicative model. Actual samples
sizes in which the test variant is typed are listed in the legend.
Power was calculated using the on-line genetic power calculator
(Purcell et al., 2003).
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this modest but discernable effect stems from two
influences, population stratification and differential ‘miss-
ingness’. Population stratification refers to the generation of
a case-control allele frequency difference due to systematic
difference in ancestry between the cases and controls, in
other words incomplete matching of cases and controls
with regard to ancestry (Thomas and Witte, 2002).
Although this effect has long been suggested as a source
of false-positive association (Lander and Schork, 1994), the
results from GWAS thus far published have empirically
confirmed the prediction that the effect would rarely
account for anything more than modest inflation of
association (Cardon and Bell, 2001). In addition the
WTCCC has shown that with very few exceptions allele
frequencies do not vary significantly across the UK thereby
confirming that within populations like the UK hidden
stratification will rarely if ever produce more than modest
inflation in the evidence for association (WTCCC, 2007).
Unfortunately the MHC is one of the loci where allele
frequencies do vary considerable across the country thereby
raising the possibility that population stratification could
confound the analysis of this locus if cases and controls are
not adequately matched. However, having completed a
GWAS it is straightforward to identify ancestry and com-
pensate for any stratification (Devlin and Roeder, 1999;
Bacanu et al., 2000; Devlin et al., 2004). By studying
individuals whose ancestry is known to involve a mix of
ethnic groups, which vary in their susceptibility to multiple
sclerosis, population stratification can actually be used to
help map risk loci (Smith et al., 2004). Employing this
admixture approach in African American patients Reich
et al. (2005) identified a region on chromosome 1 where
European ancestry was in statistically significant excess but
this group has not yet been able to fine map the region and
identify the relevant gene. Interestingly these researchers
found no evidence for any distortion in ancestry in the
MHC suggesting that the DRB1
 1503 allele which is
common in African individuals likely confers the same
risk as the DRB1
 1501 allele, which is more common in
Europeans. In short these data suggest that the difference in
risk seen between African and European individuals is
unlikely to stem from the MHC and may well be deter-
mined by the yet to be defined locus on chromosome 1.
Differential missingness refers to the allele frequency
difference that develops between cases and controls when
genotyping failure is non-random with respect to genotype
and differs in extent between cases and controls, i.e. when
there is a difference in the amount of non-random missing
information between cases and controls (Clayton et al.,
2005). In fact, genotyping failure is almost always non-
random with respect to genotype with the result that
genotyping efficiency, the extent to which genotyping is
complete, is one of the most valuable measure of data
quality. Only analysing markers with adequate levels of
genotyping efficiency and no significant difference in
genotyping efficiency between the cases and controls
minimises the effects of this phenomenon. Since the
perturbing influences of this effect are dependant upon
MAF the genotyping efficiency threshold required must be
more stringent for markers with MAF of 510%.
Recent progress
Using genomic convergence Fernald et al. (2005) identified
a short list of multiple sclerosis candidate genes showing
the greatest support for relevance in the existing literature.
Prominent amongst these was the interleukin-7 receptor
(IL7R) (Fernald et al., 2005), a gene that had previously
been identified as a candidate and studied by groups from
Australia (Teutsch et al., 2003) and Sweden (Zhang et al.,
2005). Following on from their analysis of genomic
convergence Gregory et al. (2007) established significant
association with the IL7R SNP rs6897932 (P=2.9 10
–7);
simultaneously the Swedish group reported their extended
analysis of IL7R and thereby replicated the association with
rs6897932 (Lundmark et al., 2007). This SNP codes for a
non-synonymous variation in the alternatively spliced exon
6 of the IL7R gene. In a functional assay, Gregory et al.
(2007) have also shown that the multiple sclerosis
associated allele of rs6897932 increases the proportion of
gene product in which exon 6 is skipped and for which the
receptor is therefore soluble as opposed to membrane-
bound. These observations predict that IL7 signalling
should be impaired in multiple sclerosis, an observation
which has been independently confirmed (Cox et al., 2005).
Quite why impaired IL7R signalling increases the risk of
developing multiple sclerosis remains unknown, and of
course it is always possible that the effect of this variant on
IL7 signalling is an epiphenomenon with some other as yet
untested function of this gene being more relevant to
susceptibility. IL7R is thus the first confirmed non-MHC
association in multiple sclerosis.
Alongside these candidate gene efforts, 2007 saw the
publication of two GWAS studies in multiple sclerosis. In the
first, the IMSGC screened 931 trio families (half from the US
and half from the UK) using 334 923 SNPs (IMSGC, 2007).
As would be predicted the limited power provided by 931 trio
familiesmeantthatnounequivocalassociationswereidentified
in the screening phase, outside of the expected signals from the
MHC. However, by utilizing additional controls from the
WTCCC (n=1475) and the National Institutes of Mental
Health (n=956) along with candidate gene information, a
short list of 110 loci were followed up in an additional 2931
cases and 4205 controls. In the final analysis (employing a total
of 12 360 individuals), association with rs6897932 (the IL7R
associated SNP) was confirmed and significant association was
also established with rs12722489 (P=3.0 10
–8)a n d
rs2104286 (P=2.2 10
 7) from the interleukin-2 receptor
(IL2R) gene making this the second non-MHC locus to be
established in multiple sclerosis (IMSGC, 2007). In the second
GWAS, performed by the WTCCC (Burton et al., 2007),
3126 Brain (2008),131, 3118 ^3131 S. Sawcer975 cases and 1466 controls were screened with 12 374 non-
synonymous SNPs (nsSNPs). Again, the limited power
provided by the cohort size meant that the screen failed to
identify any unequivocally associated markers. However, it is
relevant to note that rs6897932 was the eighth most associated
marker identified, confirming that a GWAS-based approach
would have identified this association had it not already been
established through the candidate gene approach.
Attempts to follow up on the other potential associations
identified in these screens are underway alongside addi-
tional screens which will help to refine the ranking of
tested variants.
Putting things in context
It is worth pausing to consider the nature of these new
findings. Taking the IL7R association as an example we can
see that the multiple sclerosis associated allele of rs6897932
has a frequency of 72% which means that ~9 out of every
10 white Europeans carry this risk allele, which therefore
certainly would qualify as a common variant. The allele is
estimated to increase the risk of the disease by a factor of
just 1.2. Using these parameters we can calculate the
significance level (P-value) that would be expected in
attempts to replicate this finding as shown in Fig. 8.
It is clear from this figure that a replication study will need
to involve at least 2000 cases and 2000 controls if it is to have
495% power to demonstrate a nominally significant P-value
of 5%. Most attempts at replication involving more than 600
cases and 600 controls will be expected to yield a P-value of
55% but not all. Studies with less than 600 cases and 600
controls are unlikely to identify even nominally significant
association. It will be important to keep these values in mind
when interpreting replication studies. If a study involving just
400 cases and 400 controls fails to identify nominally
significant association this should not be interpreted as
evidence that rs6897932 is not relevant in the tested
population. This is perhaps the least likely explanation.
Taking these estimates of effect size and allele frequency
we can calculate the lod score that rs6897932 would be
expected to generate in a set of 100 sib pairs. This turns out
to be 50.01! In short, loci such as rs6897932 will not be
expected to generate any linkage signals discernable in
previously published linkage screens. Thus, any apparent
concordance between identified susceptibility loci and
previously reported linkage peaks is entirely coincidental.
In conclusion
An analogy might serve to summarize the relative strengths of
themanyandvariedmethodswhichhavebeenusedtotryand
unravel the complex genetics underlying susceptibility to
multiple sclerosis. Epidemiological analysis might be likened
to a hand-held magnifying glass; it has allowed us to demon-
strate that there are genetic factors to be found but because of
its inherent imprecision and vulnerability to confounding is
unable to reveal any greater detail. Linkage analysis on the
other hand can be likened to a light microscope, large details
such as the relevance of the MHC can be seen but this
approach lacks the resolution needed to identify any other
detail. It would be wholly inaccurate to infer that the failure of
this insensitive instrument to identify any other detail implies
that there are no further genes involved or that additional
genes will be of no biological importance. GWAS provides us
with the equivalent of an electron microscope, using this tool
we are finally starting to identify relevant non-MHC loci and
unravel the nature of susceptibility to multiple sclerosis.
If funding agencies can be persuaded to follow this long road
to its logical conclusion and support a 10 000-patient strong
GWAS along with the necessary replication and fine-mapping
efforts we can expect that most of the relevant common
variation could be defined. Quite what the genetic landscape
ofmultiple sclerosis willlook likeis hardtopredict. Itremains
possible that any one of the ultimately identified loci could be
especially informative about the nature of the disease or that
the modest marginal effects attributable to individual loci
might interact to produce larger effects, with subsets of risk
loci implicating particularly important pathways. There is not
much evidence for this in the data available to date and in
other diseases it seems that effects are largely independent and
additive(Weedonetal.,2006),inwhichcaseweareonlylikely
to be able to interpret these data and make use of them to
define the immunological (or other) deficits which are
responsible for susceptibility to multiple sclerosis once the
catalogue of the relevant variants is comprehensive. ‘This is
not the end, it is not even the beginning of the end. But it is,
perhaps, the end of the beginning’ - Churchill 1942.
Fig. 8 Expected P-value in follow-up studies of rs6897932, the
IL7R-associated SNP.The red line indicates the expected P-value
and the dotted lines the 95% confidence intervals on this estimate
(plotted as the negative log). It can thus be expected that 95% of
the time the observed P-value with fall in this space. The blue dots
indicate the studies already reported concerning this locus (the
first two studies did not consider this variant directly but it is
expected that the observed signal was due to LD with rs6897932).
From left to right the studies areTeutsch (2003), Zhang (2005),
IMSGC (screening phase) (2007), WTCCC (2007), Lundmark
(2007) and Gregory (2007).Expected P-values and confidence
intervals were calculated using the on-line genetic power calcula-
tor (Purcell et al., 2003).
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